Total Funding
53
38
Total FundingPost-IPO Equity raised
Growth Score
-30 pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
83833
Rize Oncology develops a platform that allows to conjugate or tether donor DNA templates.
R Geoffrey Sargent, PhD: Chief Scientific Officer & Co-Founder- William Garner: Co-Founder and Director
About the Company
Rize Oncology develops the DNA Template-Nuclease-Tethering, or TNT™, platform that allows donor DNA templates to be conjugated or tethered to CRISPR/Cas9 and other nucleases. The platform improves the efficiency of programming and modifying genes.
Rize Oncology was co-founded by Har Grover, R. Geoffrey Sargent, William J. Garner, and Daren
Graham in 2018 and is headquartered in San Lorenzo, California.
